Skip to main navigation or content
Embattled biotech Vernalis has achieved a rare few victory after US-based creditor Endo Pharmaceuticals wrote off a $56m (£28.8m) loan in return for a $7m upfront payment and future US royalties on Vernalis' migraine treatment, Frova.
Advertising
Piper Jaffray believes that the company's restructuring means its cash should now last until the end of 2009 and this, combined with the imminent exit of chief executive Simon Sturge, increases its takeover potential.
Maybe someone will buy Vernalis - but we doubt it will be on terms that are attractive to shareholders. Sell at 8.3p.
The only way to access our daily share tips, analysis and profit making tools is with an IC Advantage subscription which starts from just £12.50 per month. Purchase yours here.
Subscribe to IC Advantage today, access starts from just £12.50
Use the links below to find key market data and portfolio functionality. Registration (free) may be required for some services.
© The Financial Times Limited 2009. All rights reserved. "Investors Chronicle", "FT" and "Financial Times" are trademarks of The Financial Times Limited. No part of these web pages may be reproduced or transmitted to or stored in any other website or other form of electronic retrieval system, without prior permission in writing from the editor.
Warning: Do remember, particularly if you are new to stock market investment that the prices of shares and other investments can fall sharply. You may not get back the money you originally invested. The material here is for general information only and is not intended to be relied upon for individual investment decisions. Take independent advice before making such decisions. This site is aimed at UK residents only. To read more please see our Important Warning
-IC-1.9.0c-prod - 15/05/2009 11:00:33 - stuart.turner
